Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission

Oren Pasvolsky; Rima M. Saliba; Celina Ledesma; Uday R. Popat; Amin Alousi; Amanda Olson; Betul Oran; Chitra Hosing; Qaiser Bashir; Muzaffar H. Qazilbash; Nicholas J. Short; Farhad Ravandi; Richard Champlin; Elizabeth J. Shpall; Partow Kebriaei

doi:10.1002/ajh.26789

Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission

Oren Pasvolsky, Rima M. Saliba, Celina Ledesma, Uday R. Popat, Amin Alousi, Amanda Olson, Betul Oran, Chitra Hosing, Qaiser Bashir, Muzaffar H. Qazilbash, Nicholas J. Short, Farhad Ravandi, Richard Champlin, Elizabeth J. Shpall, Partow Kebriaei

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E35-E37
Journal	American journal of hematology
Volume	98
Issue number	2
DOIs	https://doi.org/10.1002/ajh.26789
State	Published - Feb 2023

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26789

Cite this

Pasvolsky, O., Saliba, R. M., Ledesma, C., Popat, U. R., Alousi, A., Olson, A., Oran, B., Hosing, C., Bashir, Q., Qazilbash, M. H., Short, N. J., Ravandi, F., Champlin, R., Shpall, E. J., & Kebriaei, P. (2023). Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. American journal of hematology, 98(2), E35-E37. https://doi.org/10.1002/ajh.26789

Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. / Pasvolsky, Oren ; Saliba, Rima M.; Ledesma, Celina et al.
In: American journal of hematology, Vol. 98, No. 2, 02.2023, p. E35-E37.

Research output: Contribution to journal › Letter › peer-review

Pasvolsky, O , Saliba, RM, Ledesma, C, Popat, UR , Alousi, A , Olson, A , Oran, B , Hosing, C , Bashir, Q , Qazilbash, MH , Short, NJ , Ravandi, F , Champlin, R , Shpall, EJ & Kebriaei, P 2023, 'Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission', American journal of hematology, vol. 98, no. 2, pp. E35-E37. https://doi.org/10.1002/ajh.26789

@article{a9081045ae7c4ba0ac0d0f8ebbad59d9,

title = "Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission",

author = "Oren Pasvolsky and Saliba, {Rima M.} and Celina Ledesma and Popat, {Uday R.} and Amin Alousi and Amanda Olson and Betul Oran and Chitra Hosing and Qaiser Bashir and Qazilbash, {Muzaffar H.} and Short, {Nicholas J.} and Farhad Ravandi and Richard Champlin and Shpall, {Elizabeth J.} and Partow Kebriaei",

note = "Funding Information: Qaiser Bashir reports research funding from: Stemline, Takeda, GSK and Acrotech. Advisory board: Purdue; Muzaffar H. Qazilbash reports research funding from Janssen, NexImmune and Angiocrine; Farhad Ravandi reports research funding from Amgen; All other authors declare no competing financial interests. ",

year = "2023",

month = feb,

doi = "10.1002/ajh.26789",

language = "English (US)",

volume = "98",

pages = "E35--E37",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission

AU - Pasvolsky, Oren

AU - Saliba, Rima M.

AU - Ledesma, Celina

AU - Popat, Uday R.

AU - Alousi, Amin

AU - Olson, Amanda

AU - Oran, Betul

AU - Hosing, Chitra

AU - Bashir, Qaiser

AU - Qazilbash, Muzaffar H.

AU - Short, Nicholas J.

AU - Ravandi, Farhad

AU - Champlin, Richard

AU - Shpall, Elizabeth J.

AU - Kebriaei, Partow

N1 - Funding Information: Qaiser Bashir reports research funding from: Stemline, Takeda, GSK and Acrotech. Advisory board: Purdue; Muzaffar H. Qazilbash reports research funding from Janssen, NexImmune and Angiocrine; Farhad Ravandi reports research funding from Amgen; All other authors declare no competing financial interests.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85144086097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85144086097&partnerID=8YFLogxK

U2 - 10.1002/ajh.26789

DO - 10.1002/ajh.26789

M3 - Letter

C2 - 36502492

AN - SCOPUS:85144086097

SN - 0361-8609

VL - 98

SP - E35-E37

JO - American journal of hematology

JF - American journal of hematology

IS - 2

ER -

Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this